Analysis of AIDS Vaccine Patent Applied in America
10.6039/j.issn.1001-0408.2016.07.02
- VernacularTitle:在美国申请的艾滋病疫苗专利分析
- Author:
Xuemei QIN
;
Dongmei ZHANG
- Publication Type:Journal Article
- Keywords:
AIDS;
Vaccines;
Patent;
America
- From:
China Pharmacy
2016;27(7):869-871
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for AIDS vaccine R&D in China through investigating AIDS vaccine patent ap-proval in America. METHODS:By combining keywords as HIV vaccine(s),AIDS vaccine(s) and Vaccine of HIV(AIDS) and classification number as A61K,A61P and C12P,related patents were retrieved from Thomson Innovation platform during Jan. 1981-Mar. 2015,and then analyzed in respects of patent data,patent approval trend,R&D ability,patent technology field distribu-tion,etc. RESULTS:A total of 1 272 patents were retrieved,including 405 valid patents. From 1985 to 2014,there were three stages for the change of AIDS vaccine application quantity,which were slow rise,fast rise and slow decline period;on the whole, the trend was on the rise. The main players were Duke University,United States Department of Health and Human Services,Pas-teur Institute,Connaught Laboratories Limited and Merck Group. AIDS vaccine R&D focused on pharmaceutical preparation,thera-peutic activity of medicinal preparations,microorganism,enzyme,etc. American scientific research institutions focused more on pharmaceutical preparation and peptide study. CONCLUSIONS:Though the AIDS vaccine field develops slowly,the future is still promising. In this field,America has stronger patent advantage and scientific research strength. AIDS vaccine R&D concentrates on pharmaceutical preparation,therapeutic activity of medicinal preparations and composition.
